A Macau University of Science and Technology team, RETRO-EPIGERNA, secured $1 million and a finalist position in the $101 million XPRIZE Healthspan competition with an approach combining tRNA modification analysis and screening of traditional Chinese medicine compounds for antiaging activity. The university reports that p16/p21-related senescence markers fell 40–60% in clinical testing, though trial size, participant characteristics, product composition and publication status remain undisclosed.
Key Points
- Only Chinese team among ten XPRIZE Healthspan Milestone 2 awardees
- tRNA chemical tag changes used to identify aging-related targets
- Reported 40–60% drop in p16/p21 markers lacks published trial detail
Longevity Analysis
Cellular senescence markers p16 and p21 sit upstream of the low-grade inflammation that erodes immune competence, muscle repair and cognitive resilience with age, which makes any claimed 40–60% reduction worth scrutiny rather than acceptance. Translational modification of tRNA is a legitimate and underexplored regulatory layer, but an unnamed botanical formulation with undisclosed trial parameters offers clinicians no basis for interpretation. The value of this result will be determined by whether the final competition phase, which hinges on formal human trial outcomes in muscle, immune and cognitive function, produces data that can be independently read.
Original published by Longevity.Technology, by Kyle Umipig.